報價延遲最少15分鐘:2025/05/15 09:04 EDT
|
|
|
|
|
||||||||||||
|
|
|
|
|
-- 
|
|
|
| 價值評估 |
|
盈利(現時/預測)
-0.74/-0.70
|
|
企業價值
82.31M
|
| 資產負債 |
|
每股賬面淨值
1.07
|
| 現金流量 |
|
現金流量率
--
|
| 損益表 |
|
收益
103.20K
|
|
每股收益
0.48
|
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
報價延遲最少15分鐘：2025/05/15 09:04 EDT
同行比較之報價最少15分鐘延遲
|
業務概覽
|
|||
| Adagene Inc is a platform-driven, clinical-stage biopharmaceutical company engaged in transforming the discovery and development of novel antibody-based cancer immunotherapies. It is principally engaged in research, development, and production of monoclonal antibody drugs for cancers. The company's platform is designed to generate therapeutic antibody candidates with functional epitopes and species cross-reactivity, as highlighted by the company's immunotherapy pipeline. |